We investigated associations between genetic variation in candidate genes and on a genome-wide scale with warfarin maintenance dose, time in therapeutic range (TTR), and risk of major bleeding. Materials & methods: In total, 982 warfarintreated patients from the RE-LY trial were studied. Results: After adjusting for SNPs in VKORC1 and CYP2C9, SNPs in DDHD1 (rs17126068) and NEDD4 (rs2288344) were associated with dose. Adding these SNPs and CYP4F2 (rs2108622) to a base model increased R 2 by 2.9%. An SNP in ASPH (rs4379440) was associated with TTR (-6.8% per minor allele). VKORC1 was associated with time less than INR 2.0. VKORC1 and CYP2C9 were associated with time more than INR 3.0, but not with major bleeding. Conclusions: We identified two novel genes associated with warfarin maintenance dose and one gene associated with TTR. These genes need to be replicated in an independent cohort. 
Introduction
Warfarin is a commonly prescribed anti coagulant for prevention of stroke in patients with atrial fibrillation (AF). Compared to placebo, warfarin reduces the risk of stroke in AF by approximately 64%; however, the treatment also has some shortcomings, mainly high interindividual variation in dose needed to reach therapeutic effect, a narrow therapeutic range and increased risk of bleed ing [1, 2] . The anticoagulant effect of warfarin is measured by the international normalized ratio (INR). During the initiation phase of warfarin treatment, the dose is individualized through monitoring of the INR value and dose changes in order to reach and maintain a therapeutic range of anticoagulation, which commonly is INR 2.0-3.0 in AF [3] . There is a close relationship between INR and risk of bleeding where the risk increases at INR above 4 and rises sharply at INR above 5 [4] . Among other risk factors for bleeds during warfarin treatment are age, renal function, concomitant antithrombotic medication, concomitant diseases and unstable INR [4, 5] .
Genetic variability related to the anti coagulant response to warfarin, and pos sibly related to the risk of bleeding, has been intensely investigated over the last years [2, [6] [7] [8] [9] [10] . The two genes VKORC1 and CYP2C9 have been identified as the most common sources of genetic variation affect ing warfarin dose requirements along with CYP4F2 [11, 12] . In combination, variants in the two genes VKORC1 and CYP2C9 explain around 20-40% of the variance in dose needed to reach INR 2.0-3.0. The large genetic effects on warfarin dose requirements have enabled the development of pharmaco genetic dose prediction models and today prediction models exist for maintenance dose, loading dose and dose revisions [13] . Pharmacogenetic predic tion models for warfarin dose have been compared with standard care or a clinical algorithm in randomized clinical trials with varying results [14, 15] .
Patients in the warfarin arm of the genomic substudy of the RELY clinical trial are included in this genome wide association study (GWAS). We hypothesized that genetic markers other than the known CYP2C9, VKORC1 and CYP4F2 might affect warfarin mainte nance dose and that there might exist genetic variants affecting time in therapeutic range (TTR). We also investigated if any of the additional variables renal function, smoking, CYP4F2 or in this study identified genetic markers might improve performance of future prediction models for warfarin dosing. Furthermore, we investigated the possible clinical associations of the previously known variants rs9923231 from VKORC1, CYP2C9*2 and *3 and rs2108622 from CYP4F2 with TTR, time below INR 2.0, time above INR 3.0 or risk of major bleeding.
Materials & methods
RELY was a randomized clinical trial comparing two doses of dabigatran (110 or 150 mg twice daily) with warfarin for stroke prevention in 18,113 patients with documented AF and at least one additional risk fac tor for stroke. The primary efficacy end point of the RELY trial was stroke or systemic embolism and the primary safety outcome was major bleeding during a mean followup of 2 years. The study design and results have been described previously [16, 17] . In the genomic substudy of the RELY trial, 3076 patients consented to provide blood samples for DNA analy ses. The current study focuses on 982 warfarintreated patients with genetic samples.
Eligibility for the trial required documented AF and at least one of the following additional risk fac tors: first, history of previous stroke, transient isch emic attack or systemic embolism; second, ejection fraction less than 0.40; third, symptomatic heart fail ure, New York Heart Association class 2 or higher in the last 6 months; fourth, age at least 75 years or, fifth, age at least 65 years and any of diabetes mel litus, hypertension or coronary artery disease. Among the exclusion criteria were severe heart valve disor der, recent stroke, increased risk of hemorrhage, cre atinine clearance less than 30 ml/min or active liver disease. Patients on vitamin K antagonist (VKA) treatment at the time of randomization stopped their treatment on the day of randomization and began treatment at INR below 3.0 if assigned to warfarin. The local investigator was responsible for warfarin dose adjustments required to reach and maintain an INR of 2.0-3.0. After the initial dose titration phase, patients randomized to warfarin underwent INR test ing at least once a month and measures were adopted to maximize the TTR 2.0-3.0 [17] . A doseadjustment algorithm including an initiation nomogram and an action table that proposed dose adjustments was pro vided, but its use was not mandatory according to the study protocol [17] .
Study end points
Warfarin maintenance dose was calculated as the mean of all doses during stable anticoagulation periods. A stable anticoagulation period was defined as a period of at least three measures of INR within 2.0-3.0. In patients where no stable anticoagulation periods were observed, the maintenance dose was calculated as the mean of all doses associated with an INR between 2.0 and 3.0. TTR 2.0-3.0, time below INR 2.0 and time above INR 3.0 for the first 3 months (TTR 3M) and TTR during the whole treatment period (TTR Total) were calculated using linear interpolation according to the Rosendaal method [18] . TTR 3M was calculated using all values regardless of treatment initiation or interruption and TTR Total was calculated exclud ing the first 7 days of treatment and treatment inter ruptions. Major bleeding was defined as a reduction in hemoglobin concentration by at least 20 g/l, trans fusion of at least two units of blood or symptomatic bleeding in a crucial area or organ [16] . Creatinine clearance (CrCL [ml/min]) was calculated according to the Cockroft-Gault formula [16] .
Genotyping
The 982 warfarin patients with DNA samples were genotyped using the Illumina Human610quad DNA analysis BeadChip, which has 620,901 markers. Data management and quality control (QC) procedures were performed using PLINK [19] . In short, SNPs were excluded if the call rate was less than 98% or minor allele frequency (MAF) was less than 1%. The 3405 SNPs that deviated from the Hardy-Weinberg equi librium (p < 10 6 ) were flagged, but not excluded from analyses. Patients were excluded if their total call rate was less than 98%, if selfreported sex did not match genetic sex or if the genetic relatedness to another patient was high (pi_hat from PLINK >0.2). Reported genetic coordinates were based on the NCBI human genome build 36.
Statistical analysis of genome-wide data
In general, all genomewide statistical analyses of all outcomes were performed assuming an additive genetic model, in other words, the genotypes for each SNP were coded 0, 1 and 2 and handled as continuous future science group Genetic determinants of warfarin maintenance dose & time in therapeutic treatment range Research Article variables. To account for the amount of multiplicity, a pvalue threshold of genomewide significance was set at 0.05/554,725 = 9 × 10 8 according to the Bonferroni method. To account for possible population stratifica tion, all genomewide analyses were adjusted for the first four genetic principal components [20] . Further more, genomewide significant findings were validated in the large cluster 1, shown in the plot of the first two principal components in Supplementary Figure 1 , for consistency of regression coefficient (beta) estimates. The clusters were identified using kmeans clustering (the Hartigan and Wong method with k = 6) on the four first genetic principal components.
GWAS of warfarin maintenance dose was performed using linear regression on the square root of warfarin dose (transformed to obtain normality). The analy ses were adjusted by the nongenetic clinical variables from the International Warfarin Pharmacogenetics Consortium (IWPC) model and the full set of IWPC variables [7] . The full IWPC pharmaco genetic predic tion model for warfarin maintenance dose includes the following variables: age, height, weight, race, enzyme inducer status (treatment with carbamaze pine, phenytoin or rifampicin), amiodarone, VKORC1 rs9923231 and CYP2C9*2/*3.
TTR during the first 3 months and total TTR were analyzed using linear regression. Due to the low consis tency of factors affecting TTR in the literature [21, 22] , selection of variables for adjustments were driven by the data. This was done as follows for each outcome. First, univariate effects on the outcomes were esti mated. Variables with univariate p < 0.10 were ana lyzed in a multiple model and selected for inclusion for adjustment in the GWAS analyses if p < 0.10 in the multiple model. Variables with previously known clinical effect could be added to the final adjustment variables although p ≥ 0.10 based on judgment of beta estimates and precision. Assumptions of linear effect of continuous variables were inspected and where nonlinear effects were present, appropriate transfor mation was made. The variables eligible for inclusion as covariates were: age, weight (kg), height (cm), BMI (kg/m 2 ), gender, systolic and diastolic blood pressure at baseline (mmHg), CrCl (ml/min), type of AF, CHADS 2 score [23] , previous stroke, previous diabetes mellitus, previous hypertension, history of VKA use, VKA use class at entry, baseline INR, treatment with aspirin, angiotensinII receptor antagonists, ACE inhibitors, clopidogrel, amiodarone, statins, proton pump inhibitors, H2-blockers, Pglycoprotein (Pgp) inhibitors and intake of any liver enzyme inducer ( carbamazepine, phenytoin or rifampicin).
All statistical analyses on a genomewide scale were performed using GenABEL [24] . 
Imputation using reference panels
To enrich for SNPs in regions with genomewide hits, variants were imputed one megabase upstream and one megabase downstream of each hit using public available reference panels. Impute v2.2.2 was used for the imputation [25, 26] and SHAPEIT was used for pre phasing the RELY data [27] . The 1000 Genomes Phase I integrated variant set (February 2012) was used as reference set for the imputations [28] .
Statistical analysis of phenotype & candidate gene data on maintenance dose
Univariate and multiple analyses of candidate variables evaluated for predictive ability of warfarin dose were performed using linear regression on the square root transformed dose. R 2 values were reported on the origi nal scale of the variable by retransforming the predicted values and calculating the squared correlation between the predicted and observed values. To reduce the effects of overfitting, the added R 2 to the pharmaco genetic base model that included all the IWPC covariates, was evalu ated using cross validation with 10,000 resamples of data; 70% of patients as training data set and 30% of patients as validation data set. The median and the 2.5 and 97.5 percentiles of the resulting retransformed R 2 distribution were presented as point estimate and 95% confidence interval. As R 2 values can be quite abstract, we also cal culated a set of more clinically intuitive measures. These included the percentage of patients predicted within 20% of the observed dose in total and in subclasses of patients with observed dose ≤21 mg/week, >21 to <49 mg/week and ≥49 mg/week as well as the number needed to treat Genetic determinants of warfarin maintenance dose & time in therapeutic treatment range Research Article (NNT) to prevent one patient from being predicted out side 20% of the actual dose [7, 29] . Furthermore, to graph ically evaluate additional factors, we plotted the differ ence in the absolute residual of a base model to a new model including an additional covariate. In these graphs, the reported values of difference are on the original scale of the variable. A negative value indicates that the new prediction is worse and a positive value indicates that the new prediction is better.
Statistical analysis of candidate gene data on TTR & major bleeding
Univariate effects of VKORC1, CYP2C9 and CYP4F2 on TTR outcomes were evaluated using the non parametric KruskalWallis test (due to the skewed distribution of time below INR 2.0 and time above INR 3.0). Major bleeding was evaluated using Fisher's exact test and hazard ratios were estimated using Cox regression. In addition to the analysis of single variants of VKORC1 and CYP2C9, a responder category was created according to Mega et al. [30] as following:
• Normal responders: VKORC1 G/G and (CYP2C9*1/*2 or *1/*2);
• Sensitive responders: VKORC1 G/G and (CYP2C9*1/*3 or *2/*2 or *2/*3) or VKORC1 A/G and (CYP2C9*1/*2 or *1/*3 or *2/*2) or VKORC1 A/A and (CYP2C9*1/*1 or *1/*2);
• Highly sensitive responders: VKORC1 G/G and (CYP2C9*3/*3) or VKORC1 A/G and (CYP2C9*2/*3 or *3/*3) or VKORC1 A/A and (CYP2C9*1/*3 or *2/*2 or *2/*3 or *3/*3).
In the analyses of phenotype and candidate gene data, the significance level was set at 0.05. All statis tical analyses were done using R (R Foundation for Statistical Computing, Vienna, Austria).
Results

Baseline characteristics & outcomes
Baseline characteristics and outcomes are given in Table 1 . All subsequent analyses are reported based on the 956 patients and 554,725 markers that passed QC in the warfarin treatment arm. These patients had a median followup of 816 days. 81% had a history of VKA use and 40% were warfarin naive at baseline (duration of previous VKA treatment ≤2 months). The maintenance dose of warfarin could be calculated in 951 patients and the median value was 29.6 mg/week. 38 (4%) of the 951 patients did not achieve any stable anticoagulation period, hence the mean of all doses achieving INR 2.0-3.0 was used for these patients. Overall median TTR was 72.2% (mean: 70.1%), whereas the median TTR in the first 3 months was 61.7% (mean: 61.0%). Fiftythree major bleeding events were reported corresponding to an incidence rate of 2.6% per patient year.
GWAS in relation to warfarin maintenance dose
A Manhattan plot of the GWAS results for warfarin maintenance dose, adjusted for clinical factors and prin cipal components, is shown in Figure 1A . As expected, there were two major peaks in the areas around VKORC1 and CYP2C9 [12] . The top hit SNPs were in a region of high LD around VKORC1 on chromosome 16 and the SNP with the highest signal was in STX4 (rs10871454, p = 4.40 × 10 64 ) ( Table 2 & Supplementary Table 1) . However, this SNP is in high LD (r 2 = 0.994) with the third most significant SNP, rs9923231, which is the VKORC1 SNP commonly used in prediction models [6, 7, 10] . The top hit SNP in the CYP2C9 region (rs9332220, p = 5.64 × 10 32 ) is in complete LD (r 2 = 1.00) with the SNP rs4917639 that is known to tag the *2 and *3 variants in CYP2C9 (Table 2 & Supplementary Table 2 ) [2, 10] . Figure 1B shows the results of the analysis of war farin maintenance dose when, in addition to the first model, also adjusting for VKORC1 (rs9923231) and CYP2C9(*2/*3). Two SNPs reach genomewide signif icance (Table 2 & Supplementary Table 2 
GWAS in relation to TTR
Concerning TTR during the first 3 months, the results were adjusted for the following covariates that were sig nificant in our study: diastolic blood pressure at base line, previous stroke, baseline INR and the first four principal components. The results concerning total TTR were adjusted for the following factors: age, age squared (to account for nonlinear effect of age), height (cm), AF type, CHADS 2 score, previous stroke, VKA use class at entry, baseline INR, Pgp inhibitors under treatment and the first four principal components. The analysis of TTR in the first 3 months revealed no genomewide significant signals. However, for total TTR there was a genomewide significant hit in ASPH on chromosome 8 ( Figure 2 & Table 2 ), namely rs4379440 (p = 5.00 × 10 8 ). The SNP has a MAF of 7.6% and the effect on TTR was 6.8% (95% CI: 9.3 to 4.4) per minor allele. Imputation in the region around rs4379440 revealed an even stronger signal Table 4 . Estimations of clinical usefulness of potential candidates for future prediction models of warfarin dose. Added value of CYP4F2 rs2108622, DDHD1 rs17126068 and NEDD4 rs2288344 to a base prediction model including all the variables from the IWPC algorithm [7] : age, height, weight, amiodarone, inducer use, ethnicity, CYP2C9*2/*3 and VKORC1 rs9923231. Each dot illustrates a patient's difference in ABS residual between the base model and the new model. The red line is a loess smoother showing the trend in the data. ABS: Absolute. from an imputed SNP, rs17791091 (p = 4.13 × 10 9 ). It has an MAF of 6.9% and the effect on TTR was 7.8% (95% CI: 10.5 to 5.2) per minor allele. This SNP is positioned in the intron region of ASPH close to the typed rs4379440 SNP, which also is located in the intron, the LD (r 2 ) between them is 0.936. Subgroup analysis was performed for rs4379440 in the largest cluster (based on PCA) to rule out the risk of confounding by population stratification. The effects on total TTR were similar and are presented in Supplementary Table 4 .
Evaluation of additional variables for dose prediction models
We evaluated a list of phenotypes and genotypes that could be candidates to be included in future prediction models for warfarin dosing. The variables evaluated were CrCl, smoking and CYP4F2 rs2108622 with the addition of the novel two SNPs found in this GWAS: DDHD1 rs17126068 and NEDD4 rs2288344. The univariate and adjusted effects on dose are shown in Table 3 . CrCl showed a large univariate effect with an R 2 of 9.6% (beta = 0.013; p = 6.30 × 10 23 ), but much of this effect was due to the correlation of CrCl with age (r = 0.60) and weight (r = 0.69). When add ing CrCl to a base model including the variables used in the IWPC model [7] , the added R 2 was 0.4% but CrCl was still statistically significant (beta = 0.005; p = 6.51 × 10 4 ). As an example, the lowering of dose for patients moving from the median CrCl in this study of 73 to 30 ml/min is 1.3 mg/week (13.1%) for patients with a 10 mg/week dose, 2.3 mg/week (7.7%) for patients with a 30mg/week dose and 3.0 mg/week (6.0%) for patients with a 50mg/week dose. Smoking showed no signs of being important for determination of warfarin dose (adjusted p = 0.279). All three SNPs evaluated (CYP4F2 rs2108622, DDHD1 rs17126068 and NEDD4 rs2288344) had statistically significant Table 4 [7] . The NNT to prevent one patient from being predicted outside 20% of the actual dose was negative for CrCl and smoking (951 and 476, respectively) indicating that these factors would not improve dosing accuracy. The genetic fac tors CYP4F2 rs2108622, DDHD1 rs17126068 and NEDD4 rs2288344 presented with positive NNT values of 317, 476 and 136, respectively. All variables with positive NNT (i.e., the genetic factors) were used in a combined model resulting in a NNT of 106. An illustration of the performance of this model compared with the base model is shown in Figure 3 . For compari son, adding CYP2C9*2/*3 and VKORC1 rs9923231 to a clinical model including all nongenetic variables from the IWPC model was also calculated (Table 4) . Adding VKORC1 rs9923231 and CYP2C9*2/*3 to the clinical model gives a NNT of 7, an illustration of the performance of this model compared with the clinical model is shown in Figure 4 .
Effects of VKORC1, CYP2C9 & CYP4F2 on time in or out-of-range & major bleeding VKORC1 rs9923231, CYP2C9*2, *3 and the *2/*3 composite, CYP4F2 and the responder categories according to Mega et al. [30] were evaluated against time below INR 2. . No other time in or outof range outcomes were statistically significant for either TTR during the first 3 months or in total. However, trends toward what would be expected for CYP2C9*3 could be seen for all time in or outofrange outcomes ( Figure 5 ). There was no significant difference between the numbers of major bleeding events for the geno types of the analyzed markers (Table 5) .
Discussion
We performed a genomewide association study on 956 warfarintreated patients from the RELY study. The major findings were two novel genes affecting warfarin maintenance dose as well as one novel gene affecting TTR.
In concordance with previous GWAS of warfarin maintenance dose on patients of mainly European descent, we found major peaks around CYP2C9 and VKORC1 [12, 31] . After adjustment of CYP2C9 (*2 and *3), VKORC1 (rs9923231) and clinical covariates, we found two novel genes affecting warfarin main tenance dose. The findings were located in or close to DDHD1 (rs17126068) on chromosome 14 and NEDD4 (rs2288344) on chromosome 15. DDHD1 is a phospholipase that hydrolyzes phosphatidic acid. NEDD4 is an E3 ubiquitinprotein ligase and a receptorpotentiating factor.
The GWAS analyses of warfarin maintenance dose were followed up by investigating the effect of adding the new novel markers as well as other known variables that affect warfarin maintenance dose (CrCl, smoking and CYP4F2 rs2108622) to a warfarin dose predic [30] , Normal responders: VKORC1 G/G and (CYP2C9*1/*2 or *1/*2); Sensitive responders: VKORC1 G/G and (CYP2C9*1/*3 or *2/*2 or *2/*3) or VKORC1 A/G and (CYP2C9*1/*2 or *1/*3 or *2/*2) or VKORC1 A/A and (CYP2C9*1/*1 or *1/*2); Highly sensitive responders: VKORC1 G/G and (CYP2C9*3/*3) or VKORC1 A/G and (CYP2C9*2/*3 or *3/*3) or VKORC1 A/A and (CYP2C9*1/*3 or *2/*2 or *2/*3 or *3/*3).
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Research Article Eriksson, Wallentin, Berglund et al. tion model including the covariates used in the IWPC prediction model [7] . The genetic variables CYP4F2 (rs2108622), DDHD1 (rs17126068) and NEDD4 (rs2288344) showed promising results with an added R 2 of approximately 1% each or approximately 3% combined. However, given that adding the three genetic factors gave a NNT of 106 while doubling the number of SNPs that have to be genotyped, one can hypothesize that prospective genotyping of these addi tional SNPs is not cost effective in clinical practice. Although there might exist rare variants affecting war farin sensitivity or resistance, this study indicates that for patients of European descent, the published clinical trials utilizing pharmacogenetic driven warfarin dos ing were performed using appropriate genetic variants of VKORC1 and CYP2C9 [14, 15] .
Interestingly, our study shows no effect of smoking on warfarin maintenance dose. Smoking is thought to potentially increase warfarin metabolism, and to increase warfarin maintenance doses by approximately 10% compared with nonsmokers; however, there is also conflicting evidence showing no effect of smoking [32] .
To our knowledge, this is the first study reporting GWAS results on TTR. For TTR during the whole treatment period, a genomewide significant signal was found in ASPH (rs4379440) on chromosome 8. ASPH is thought to play an important role in calcium homeostasis. The gene is expressed from two promot ers and undergoes extensive alternative splicing. The longest isoforms (a and f) include a Cterminal domain that hydroxylates aspartic acid or asparagine residues of some proteins, including protein C, coagulation fac tors VII, IX, and X, and the complement factors C1R and C1S [33] .
When analyzing the effect of the established warfa rinrelated genes VKORC1 rs9923231, CYP2C9*2/*3 and CYP4F2 rs2108622 on time in and outofTTR, rs9923231 was associated with both time below INR 2.0 and time above INR 3.0 during the first 3 months. Furthermore, CYP2C9*3 was associated with time above INR 3.0 during the first 3 months. The responder categories according to Mega et al. [30] , which combines VKORC1 and CYP2C9, also had effect on INR above 3.0 and below 2.0 during the first 3 months. These results are in line with previous results on TTR mea sures showing that VKORC1 does have modest effect on the stability of anticoagulation in patients on warfa rin, whereas the largest effect (the lowest TTR) is seen in patients homozygous for the CYP2C9*3 allele [10, 34] . We saw no statistically significant effects on TTR dur ing the whole treatment period. This could be due to the effect of genetic factors affecting dose which in turn affects TTR are expected to diminish over time as patient dosing is data driven and adjusted according to the INR value. Thus, TTR in the long term is expected to be more dependent on the skill of the person doing the dosing or if algorithm based dosing is used, as was encouraged in the RELY trial [35] .
Our study did not show an effect of VKORC1 or CYP2C9 on the hard outcome major bleeding. The ENGAGE AFTIMI 48 trial with 4833 warfarin treated patients showed an increased risk of bleed ing during the first 3 months in warfarinsensitive patients [30] . Patients were classified as sensitive if they carried the following combinations of vari ants: CYP2C9*1/*3, *2/*2, *2/*3 or *3/*3 with any VKORC1 genotype, in addition *1/*2 with VKORC1 A/G or VKORC1 A/A and *1/*1 with VKORC1 A/A. A conclusion from the ENGAGE trial was that non vitamin K oral anti coagulants could be reserved for individuals classified as sensitive responders and there fore more likely to experience early warfarin bleed ing [36] . We used the same definition of responder as in the ENGAGE AFTIMI 48 trial but did not see any increased risk of major bleeding in the sensitive categories.
There are limitations to this study. First of all, only 40% of patients were warfarin naive at baseline and 76% of the patients were on oral anti coagulants at baseline, which affects TTR measurements. Although we could see genetic effects on TTR in the first 3 months, these results are probably underestimated due to the number of patients on oral anticoagulants at baseline. Second, a majority of the patients are white (87%) with a low percentage of Asians (2%) and Africans (1%) why the results are not generalizable to these ethnic groups. Third, no patients with severe renal impairment (CrCl <30 ml/min) were included in the RELY study creatinine clearance <30 ml/min was an exclusion criterion. Fourth, multiple outcomes were studied that increase the chance of spurious find ings and the novel findings against warfarin dose were found after adjusting for the previously known variants in VKORC1 and CYP2C9. Fifth, the genomewide hits found in this study, have not yet been replicated in an independent cohort. And last, even though the study was fairly large with 982 warfarintreated patients, it was underpowered with respect to the outcome major bleeding.
Conclusion
We conducted a GWAS analyzing warfarin maintenance dose and TTR in the warfarintreated patients from the RELY genomics study. For both outcomes, we identi fied novel genomewide significant findings. The main finding in the current study was the identification of two novel SNPs having an effect on warfarin maintenance dose. However, these SNPs provide limited incremental future science group 
Executive summary
Objective
• Warfarin treatment has some shortcomings, mainly high inter-individual variation in dose needed to reach therapeutic effect, a narrow therapeutic range and increased risk of bleeding. We hypothesized that genetic markers other than the known CYP2C9, VKORC1 and CYP4F2, might affect warfarin maintenance dose and that there might exist genetic variants affecting time in therapeutic treatment range (TTR).
Materials & methods
• Patients in the warfarin arm of the genomic substudy of the RE-LY clinical trial are included in this genomewide association study (GWAS).
• Outcomes analyzed on a GWAS scale were: warfarin maintenance dose, TTR within 3 months and TTR in total.
• TTR, as well as time below INR 2.0 and time above INR 3.0, was evaluated within 3 months and in total were analyzed for the genetic factors rs9923231 of VKORC1, *2/*3 of CYP2C9, rs2108622 of CYP4F2 and sensitivity groups based on VKORC1 and CYP2C9. The same genetic variables were also analyzed versus major bleeding.
Results
• Novel genome-wide significant SNPs affecting warfarin dose were found in DDHD1 (rs17126068) and NEDD4 (rs2288344). Adding the new SNPs to a model including VKORC1 (rs9923231), CYP2C9 (*2/*3) and clinical factors increased R 2 by 2.9%.
• A SNP in ASPH (rs4379440) on chromosome 8 was associated with TTR in total (-6.8% per minor allele).
• During the first 3 months, VKORC1 (rs9923231) was associated with time below INR 2.0 (p = 6.35 × 10 -4 ) and time above INR 3.0 (p = 1.11 × 10 -2 ). CYP2C9 (*2/*3) was associated with time above INR 3.0 (p = 9.21 × 10 -4 ). Combining VKORC1 and CYP2C9 into sensitivity groups affected the same TTR measures as the individual variants. No other time in or out-of-range outcomes were statistically significant for either TTR during the first 3 months or in total.
• Major bleeding was not significantly associated with either VKORC1, CYP2C9*2/*3 or CYP4F2 genotypes as well as sensitivity groups defined by VKORC1 and CYP2C9.
Conclusion
• We identified two novel genes, DDHD1 (rs17126068) and NEDD4 (rs2288344), associated with warfarin maintenance dose and one gene, ASPH (rs4379440), associated with TTR.
• The incremental information provided by these SNPs for prediction of a patient's dose is probably limited.
